Comment
doi: 10.3322/caac.21375.
Epub 2017 Jul 11.
Encouraging long-term outcomes reported in patients with stage I non-small cell lung cancer treated with stereotactic ablative radiotherapy
- PMID: 28697271
- DOI: 10.3322/caac.21375
Item in Clipboard
Comment
Encouraging long-term outcomes reported in patients with stage I non-small cell lung cancer treated with stereotactic ablative radiotherapy
CA Cancer J Clin.
2017 Sep.
Free article
No abstract available
Comment on
-
7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.Cancer. 2017 Aug 15;123(16):3031-3039. doi: 10.1002/cncr.30693. Epub 2017 Mar 27. Cancer. 2017. PMID: 28346656 Free PMC article. Clinical Trial.
Similar articles
-
7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.Cancer. 2017 Aug 15;123(16):3031-3039. doi: 10.1002/cncr.30693. Epub 2017 Mar 27. Cancer. 2017. PMID: 28346656 Free PMC article. Clinical Trial.
-
Stereotactic ablative radiation therapy for primary lung tumors.Cancer J. 2011 Jan-Feb;17(1):28-32. doi: 10.1097/PPO.0b013e31820a7f80. Cancer J. 2011. PMID: 21263264 Review.
-
Stereotactic Body Radiotherapy and Ablative Therapies for Lung Cancer.Surg Oncol Clin N Am. 2016 Jul;25(3):553-66. doi: 10.1016/j.soc.2016.02.008. Surg Oncol Clin N Am. 2016. PMID: 27261915 Review.
-
Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.Discov Med. 2010 May;9(48):411-7. Discov Med. 2010. PMID: 20515609 Review.
-
Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial.Radiother Oncol. 2015 Oct;117(1):44-8. doi: 10.1016/j.radonc.2015.08.011. Radiother Oncol. 2015. PMID: 26492839 Clinical Trial.
Cited by
-
The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.EBioMedicine. 2018 Sep;35:204-221. doi: 10.1016/j.ebiom.2018.08.001. Epub 2018 Aug 23. EBioMedicine. 2018. Retraction in: EBioMedicine. 2021 Jan;63:103168. doi: 10.1016/j.ebiom.2020.103168. PMID: 30146342 Free PMC article. Retracted.
-
Modern Radiation Further Improves Survival in Non-Small Cell Lung Cancer: An Analysis of 288,670 Patients.J Cancer. 2019 Jan 1;10(1):168-177. doi: 10.7150/jca.26600. eCollection 2019. J Cancer. 2019. PMID: 30662537 Free PMC article.
-
Knockdown of ubiquitin-conjugating enzyme E2T (UBE2T) suppresses lung adenocarcinoma progression via targeting fibulin-5 (FBLN5).Bioengineered. 2022 May;13(5):11867-11880. doi: 10.1080/21655979.2022.2060162. Bioengineered. 2022. PMID: 35543375 Free PMC article.
-
UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.Theranostics. 2019 Mar 17;9(7):2036-2055. doi: 10.7150/thno.32738. eCollection 2019. Theranostics. 2019. Retraction in: Theranostics. 2020 Jul 25;10(21):9619. doi: 10.7150/thno.50254. PMID: 31037155 Free PMC article. Retracted.
-
Timosaponin AIII promotes non-small-cell lung cancer ferroptosis through targeting and facilitating HSP90 mediated GPX4 ubiquitination and degradation.Int J Biol Sci. 2023 Feb 27;19(5):1471-1489. doi: 10.7150/ijbs.77979. eCollection 2023. Int J Biol Sci. 2023. PMID: 37056925 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
